Sudeep Pharma quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	197	163	+20.9%
EBITDA	73.2	55.5	+32.1%
EBITDA margin	37.2%	34.1%	+3.1 pts
Profit before tax	71.0	59.5	+19.3%
Net profit	51.8	46.8	+10.8%
EPS	₹4.59	₹4.20	+9.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025

Expenses
	197	158	182	172	163
	6.0	5.4	6.4	6.8	10.2
	203	164	189	179	173
	71.4	68.8	71.1	70.3	70.5
	−1.9	−12.2	−7.3	−10.1	−9.5
	15.6	14.3	10.5	15.0	14.1
	2.8	2.1	2.4	1.2	2.3
	5.4	4.0	3.9	3.9	3.8
	38.3	32.4	45.4	37.1	32.2
	132	109	126	117	113
	73.2	54.9	62.6	60.0	55.5
	67.9	50.9	58.7	56.1	51.7
Profit
	71.0	54.3	62.7	61.8	59.5
	71.0	54.3	62.7	61.8	59.5
	18.2	12.3	12.7	13.7	12.2
	1.0	1.4	1.5	0.4	0.6
	19.2	13.7	14.2	14.1	12.8
	51.8	40.6	48.5	47.7	46.8
	51.8	40.6	48.5	47.7	46.8
	−0.2	−0.1	6.2	−2.0	−2.6
	51.6	40.5	54.7	45.7	44.2
	—	40.6	48.9	47.6	45.7
	—	0.0	−0.3	0.1	1.0
Per share
	₹4.59	₹3.59	₹4.38	₹4.29	₹4.20
	₹4.59	₹3.59	₹4.38	₹4.29	₹4.20
Other comprehensive income — detail
	−0.2	−0.1	6.2	−2.0	−2.6
	—	0.1	—	−0.4	—
	0.2	0.0	−0.2	−0.1	−0.2
	—	−0.1	—	−1.6	—
	0.0	0.0	−5.9	0.0	2.7
	51.5	40.5	55.0	45.4	43.2
	0.4	0.0	−0.3	0.3	1.0
Per share — as-filed variants
	₹4.59	₹3.59	₹4.38	₹4.29	₹4.20
	₹4.59	₹3.59	₹4.38	₹4.29	₹4.20
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	127	102	118	112	102
	64.7%	64.2%	65.0%	65.1%	62.5%
Adjusted (ex-exceptional items) — derived
	71.0	54.3	62.7	61.8	59.5
	51.8	40.6	48.5	47.7	46.8
	₹4.59	₹3.59	₹4.38	₹4.29	₹4.20

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUDEEPPHRM₹1,130.10

Sudeep Pharma Ltd.

· Chemicals

Annual Quarterly₹ CrorePeersSUDARSCHEM STYRENIX SHARDACROP REFEX RCF RALLIS RAIN PRIVISCLMcap ₹12,764 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	162.7	172.3	182.3	158.3	196.7
Other Income	10.2	6.8	6.4	5.4	6.0
Total Income	172.8	179.2	188.8	163.7	202.7
Expenses
+ Cost of Materials Consumed	70.5	70.3	71.1	68.8	71.4
+ Changes in Inventories	-9.5	-10.1	-7.3	-12.2	-1.9
+ Employee Benefit Expense	14.1	15.0	10.5	14.3	15.6
+ Finance Costs	2.3	1.2	2.4	2.1	2.8
+ Depreciation & Amortisation	3.8	3.9	3.9	4.0	5.4
+ Other Expenses	32.2	37.1	45.4	32.4	38.3
Total Expenses	113.3	117.4	126.1	109.4	131.7
EBITDA	55.5	60.0	62.6	54.9	73.2
EBIT	51.7	56.1	58.7	50.9	67.9
Profit
PBT before Exceptional Items	59.5	61.8	62.7	54.3	71.0
Pretax Income	59.5	61.8	62.7	54.3	71.0
+ Current Tax	12.2	13.7	12.7	12.3	18.2
+ Deferred Tax	0.6	0.4	1.5	1.4	1.0
Tax Expense	12.8	14.1	14.2	13.7	19.2
Net Income	46.8	47.7	48.5	40.6	51.8
+ Net Income — Continuing Ops	46.8	47.7	48.5	40.6	51.8
+ Other Comprehensive Income	-2.6	-2.0	6.2	-0.1	-0.2
Total Comprehensive Income	44.2	45.7	54.7	40.5	51.6
Net Income to Common	45.7	47.6	48.9	40.6	—
Minority Interest	1.0	0.1	-0.3	0.0	—
Per Share
Basic EPS	4.20	4.29	4.38	3.59	4.59
Diluted EPS	4.20	4.29	4.38	3.59	4.59
Other Comprehensive Income — detail
+ Other Comprehensive Income	-2.6	-2.0	6.2	-0.1	-0.2
+ Items NOT to be Reclassified to P&L	—	-0.4	—	0.1	—
+ Tax on Items NOT to be Reclassified	-0.2	-0.1	-0.2	0.0	0.2
+ Items to be Reclassified to P&L	—	-1.6	—	-0.1	—
+ Tax on Items to be Reclassified	2.7	0.0	-5.9	0.0	0.0
Comprehensive Income — Owners of Parent	43.2	45.4	55.0	40.5	51.5
Comprehensive Income — Non-controlling Interests	1.0	0.3	-0.3	0.0	0.4
Per Share — as-filed variants
Basic EPS — Continuing Operations	4.20	4.29	4.38	3.59	4.59
Diluted EPS — Continuing Operations	4.20	4.29	4.38	3.59	4.59
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	101.7	112.1	118.5	101.7	127.2
Gross Margin %	62.54	65.07	64.98	64.24	64.66
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	59.5	61.8	62.7	54.3	71.0
Net Income Adj (tax-effected)	46.8	47.7	48.5	40.6	51.8
EPS Adj	4.20	4.29	4.38	3.59	4.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	—
Paid Up Equity Capital	9.7	11.3	11.3	11.3	—

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Sudeep Pharma Q2 FY27 results (July–September 2026)

Sudeep Pharma (NSE: SUDEEPPHRM) reported its Q2 FY27 results (July–September 2026). Consolidated net profit was ₹51.8 crore, up 13.3% from ₹45.7 crore in Q2 FY26 and up 27.8% from ₹40.6 crore in Q1 FY27. Revenue from operations was ₹197 crore, up 20.9% year on year and up 24.3% from the previous quarter.

Q2 FY26 results (a year earlier): 19 December 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹51.8 Cr+13.3% vs Q2 FY26+27.8% vs Q1 FY27
Revenue from operations: ₹197 Cr+20.9% vs Q2 FY26+24.3% vs Q1 FY27
Operating margin (EBIT): 34.5%+2.7 pts vs Q2 FY26+2.3 pts vs Q1 FY27EBIT ₹67.9 Cr
EBITDA: ₹73.2 Cr+32.1% vs Q2 FY26+33.4% vs Q1 FY27margin 37.2%
Earnings per share (basic): ₹4.59+9.3% vs Q2 FY26+27.9% vs Q1 FY27
Net profit margin: 26.3%−1.8 pts vs Q2 FY26+0.7 pts vs Q1 FY27

Questions

What was Sudeep Pharma's net profit in Q2 FY27?

Consolidated net profit was ₹51.8 crore, up 13.3% from ₹45.7 crore in Q2 FY26 and up 27.8% from ₹40.6 crore in Q1 FY27.

How were Sudeep Pharma's Q2 FY27 results?

Both grew from a year earlier: net profit was up 13.3% at ₹51.8 crore and revenue was up 20.9% at ₹197 crore. The operating margin was 34.5%, up 2.7 percentage points from 31.8% a year earlier. Against Q1 FY27, net profit was up 27.8% and revenue up 24.3%.

What is Sudeep Pharma's net profit margin?

Sudeep Pharma's net profit margin was 26.3% in Q2 FY27 (net profit as a share of revenue from operations), against 28.1% in Q2 FY26 (down 1.8 percentage points). For FY26 as a whole it was 26.9%.

What was Sudeep Pharma's revenue in Q2 FY27?

Revenue from operations was ₹197 crore, up 20.9% year on year and up 24.3% from the previous quarter.

What was Sudeep Pharma's EPS in Q2 FY27?

Basic earnings per share were ₹4.59, against ₹4.20 in Q2 FY26.

What was Sudeep Pharma's net profit in FY26?

Consolidated net profit was ₹173 crore in FY26 (April 2025–March 2026).

What was Sudeep Pharma's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹67.9 crore, a margin of 34.5%, against 32.2% in Q1 FY27 and 31.8% in Q2 FY26. EBITDA was ₹73.2 crore, 37.2% of revenue.

How has Sudeep Pharma's profit changed over the last four quarters?

Net profit by quarter: ₹47.6 crore in Q3 FY26, ₹48.9 crore in Q4 FY26, ₹40.6 crore in Q1 FY27 and ₹51.8 crore in Q2 FY27. That is ₹189 crore over the four quarters. Revenue from operations: ₹172 crore, ₹182 crore, ₹158 crore and ₹197 crore.

When will Sudeep Pharma announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

What was Sudeep Pharma's revenue in FY26?

Revenue from operations was ₹642 crore in FY26 (April 2025–March 2026).

Where do these Sudeep Pharma figures come from?

From Sudeep Pharma's own consolidated results filings to NSE, in ₹ crore as filed. Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.